Alzheimer's disease and other dementias: Advances in 2013

The Lancet Neurology

Volumn 13, Issue 1, 2014, Pages 3-5

  Reiman, Eric M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE QUALITY; HUMAN; IMMUNIZATION; IMMUNOCOMPETENT CELL; INFLAMMATION; MEDICAL RESEARCH; MILD COGNITIVE IMPAIRMENT; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PREVENTION STUDY; PRIORITY JOURNAL; REIMBURSEMENT; TAUOPATHY;

ALZHEIMER DISEASE; DEMENTIA; HUMANS; STANDARD OF CARE;

EID: 84892142235     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70257-6     Document Type: Note

References (15)

1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
2. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012, 11:1057-1065.
3. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
4. Knickmeyer RC, Wang J, Zhu H, et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb Cortex 2013, published online Jan 2. 10.1093/cercor/bhs401.
5. Dean CD, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 2013, published online Nov 25. 10.1001/jamaneurol.2013.4544.
6. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013, 9:e1-16.
7. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013, 34:457-468.
8. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013, 54:1420-1427.
9. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 18:1094-1108.
10. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014, 38:171-184.
11. Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vitro. Neuron 2013, 80:402-414.
12. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013, published online Oct 27. 10.1038/ng.2802.
13. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013, 368:107-116.
14. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013, 368:117-127.
15. Kozauer N, Katz R Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013, 368:1169-1171.